Cancer in China: Understanding the Scale
China bears one of the heaviest cancer burdens in the world. According to data from the National Cancer Center of China, approximately 4.82 million new cancer cases were diagnosed in China in 2022, and an estimated 3.21 million cancer-related deaths occurred in the same year. Cancer has surpassed cardiovascular disease as the leading cause of death in several Chinese provinces, and the trend is expected to continue as the population ages.
These numbers are sobering. But they contain an important and often overlooked dimension: a significant proportion of these deaths are preventable — not through new drugs or experimental therapies, but through earlier detection using tools that already exist.
The Five Most Common Cancers in China
Understanding which cancers are most prevalent in China is the starting point for designing an effective screening strategy. The five highest-incidence cancers in China are:
- Lung cancer — the most common cancer and the leading cause of cancer death in China, accounting for approximately 106 deaths per 100,000 population annually.
- Colorectal cancer — incidence has risen sharply over the past two decades, driven by dietary and lifestyle changes.
- Gastric (stomach) cancer — China accounts for nearly 44% of global gastric cancer cases, with particularly high rates in certain provinces.
- Liver cancer (hepatocellular carcinoma) — China accounts for approximately 45% of global liver cancer cases, closely linked to the high prevalence of chronic hepatitis B infection.
- Breast cancer — the most common cancer among Chinese women, with incidence rising steadily in urban populations.
Each of these cancers has a well-established screening pathway. And for each of them, the data on early detection is unambiguous.
Lung Cancer: The Deadliest, and the Most Screenable
Lung cancer kills more people in China than any other cancer. The five-year survival rate for lung cancer overall remains below 20% — primarily because the vast majority of cases are diagnosed at an advanced stage, when the cancer has already spread beyond the lung.
When lung cancer is detected at Stage I (localized to the lung, no lymph node involvement), the five-year survival rate rises to approximately 70–90%, depending on the specific subtype and treatment. At Stage IV (metastatic), it falls to less than 5%.
Low-dose computed tomography (LDCT) of the chest is the only screening tool proven in large randomized trials to reduce lung cancer mortality. The landmark US National Lung Screening Trial (NLST) demonstrated a 20% reduction in lung cancer mortality among high-risk individuals screened with annual LDCT compared to chest X-ray. Subsequent European trials have shown even larger reductions.
In China, national guidelines now recommend annual LDCT for high-risk individuals aged 50–74 with a significant smoking history. The technology is widely available at Shanghai's major hospitals, and the scan itself takes less than 10 minutes.
Liver Cancer: A Preventable Tragedy
China's liver cancer burden is closely tied to its high prevalence of chronic hepatitis B infection — estimated to affect approximately 86 million people in China. Chronic hepatitis B is the primary risk factor for hepatocellular carcinoma (HCC), and the progression from chronic infection to cirrhosis to cancer can take decades — often without symptoms.
The five-year survival rate for liver cancer detected at an early, resectable stage is approximately 50–70% with surgical resection or ablation. For advanced-stage liver cancer, the five-year survival rate drops to less than 10%.
The recommended screening protocol for hepatitis B carriers and other high-risk individuals is straightforward: abdominal ultrasound and serum AFP (alpha-fetoprotein) every six months. This combination has been shown to detect HCC at an earlier, more treatable stage in high-risk populations. It is inexpensive, non-invasive, and widely available.
Yet surveillance rates among hepatitis B carriers in China remain low. Many carriers are unaware of their status; others know but do not follow through with regular monitoring. This is one of the most significant missed opportunities in Chinese preventive medicine.
Gastric Cancer: An Early-Detection Success Story From Japan and Korea
China's gastric cancer mortality rate is among the highest in the world. Yet neighboring Japan and South Korea — which have implemented national gastric cancer screening programs — have demonstrated that mass screening can dramatically shift the stage distribution at diagnosis and improve survival outcomes.
In Japan, where endoscopic screening is widely practiced, approximately 50% of gastric cancers are detected at an early stage, with five-year survival rates exceeding 90% for early gastric cancer. In China, where screening is less systematic, the majority of gastric cancers are still diagnosed at an advanced stage, with overall five-year survival rates of approximately 35%.
Gastroscopy (upper endoscopy) is the gold standard for gastric cancer screening. Chinese national guidelines recommend gastroscopy for adults over 45 in high-risk regions, or for those with risk factors including H. pylori infection, a family history of gastric cancer, or a history of chronic gastritis or gastric ulcer.
H. pylori eradication — a simple antibiotic course following confirmed infection — has been shown to reduce gastric cancer risk by approximately 35–45% in infected individuals. Testing for H. pylori is a low-cost, high-impact component of any comprehensive checkup in China.
Colorectal Cancer: The Most Preventable Cancer
Colorectal cancer is unique among major cancers in that it is not only detectable early but actively preventable through screening. The disease typically begins as a benign adenomatous polyp that may take 10–15 years to develop into invasive cancer. During this entire period, colonoscopy can identify and remove the polyp — eliminating the cancer before it begins.
The five-year survival rate for colorectal cancer detected at Stage I is approximately 90–95%. At Stage IV, it falls to 10–15%. The difference between these outcomes is, in many cases, simply whether a colonoscopy was performed on schedule.
Colorectal cancer incidence in China has increased by more than 50% over the past two decades, driven by dietary westernization, reduced physical activity, and rising obesity rates. Chinese national guidelines recommend colorectal cancer screening beginning at age 45 for average-risk individuals, with colonoscopy as the preferred method.
Breast Cancer: Rising Incidence, Improving Survival
Breast cancer is the most common cancer among Chinese women, with incidence rates in urban areas approaching those seen in Western countries. The good news is that breast cancer, when detected early, is highly treatable.
The five-year survival rate for breast cancer detected at Stage I is approximately 95–99%. At Stage IV, it falls to approximately 25–30%. Mammography screening has been shown in multiple large trials to reduce breast cancer mortality by 15–20% in screened populations.
In China, breast cancer tends to present at a younger age than in Western populations, and breast tissue density is often higher — which can reduce mammography sensitivity. For this reason, ultrasound is frequently used alongside mammography in Chinese screening protocols, and some guidelines recommend beginning screening at age 40 rather than 45–50.
What the Data Tells Us
Across all five of these cancers, the pattern is consistent: early-stage detection is associated with dramatically better survival, and effective screening tools exist for all of them. The gap between early-stage and late-stage survival rates is not marginal — it is the difference between a curable disease and a terminal one.
The barrier is not medical technology. Shanghai's leading hospitals are equipped with state-of-the-art imaging, endoscopy, and laboratory facilities that match or exceed international standards. The barrier is behavioral: the tendency to seek care only when symptoms appear, and to underestimate personal risk.
Regular, systematic cancer screening is not a luxury. For adults over 40 — particularly those with risk factors — it is one of the highest-return investments in personal health available.
A Note for International Patients in Shanghai
For expatriates and international visitors in Shanghai, accessing cancer screening at the city's top hospitals is more straightforward than many people assume. China Medical Concierge Shanghai (CMCS) helps international patients identify the right screening tests for their age and risk profile, navigate the appointment process, and understand their results — with full language support throughout. If you'd like to discuss your cancer screening options, we're here to help.
0 則留言